SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations
The beneficial effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown recently in numerous randomized controlled trials (RCT) and systematic reviews. According to KDIGO guidelines, SGLT2i currently represent a first choice for diabetic patients with chronic kidney disease (CKD)...
Main Authors: | Erietta Polychronopoulou, Fanny Bourdon, Daniel Teta |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-04-01
|
Series: | Frontiers in Nephrology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneph.2024.1332397/full |
Similar Items
-
Diabetic Kidney Disease in Post-Transplant Diabetes Mellitus: Causes, Treatment and Outcomes
by: Lee-Moay Lim, et al.
Published: (2023-02-01) -
Post transplantation diabetes mellitus in kidney allograft recipients: Current concepts
by: Nwankwo Emeka, et al.
Published: (2008-01-01) -
Home-Based Exercise Training and Cardiac Autonomic Neuropathy in Kidney Transplant Recipients with Type-II Diabetes Mellitus
by: Vassiliki Michou, et al.
Published: (2023-06-01) -
Differences between Very Highly Sensitized Kidney Transplant Recipients as Identified by Machine Learning Consensus Clustering
by: Charat Thongprayoon, et al.
Published: (2023-05-01) -
Ongoing donor-transmitted diabetic kidney disease in kidney transplant recipients with fair sugar control: a single center retrospective study
by: Chia-Tien Hsu, et al.
Published: (2020-11-01)